Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Limertinib - Jiangsu Aosaikang Pharmaceutical

Next Previous
Search
Drug Profile

Limertinib - Jiangsu Aosaikang Pharmaceutical

Alternative Names: ASK 120067

Latest Information Update: 06 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Aosaikang Pharmaceutical
  • Developer Innovent Biologics; Jiangsu Aosaikang Pharmaceutical
  • Class Amides; Anilides; Aniline compounds; Anisoles; Antineoplastics; Aromatic hydrocarbons; Chlorinated hydrocarbons; Ethylenediamines; Naphthalenes; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 26 Apr 2025 Registered for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in China (PO)
  • 26 Apr 2025 Efficacy and adverse events data from a phase III trial in Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) released by Innovent Biologics
  • 21 Jan 2025 Launched for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO), before January 2025 - First global launch (Innovent Biologics pipeline, January 2025)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top